Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45

The goal of this clinical trial is to learn about how a migraine prevention medicine works for people who have migraines/headaches with their menstrual period. The study includes people ages 18 to 45 who have been diagnosed with migraine and who have a migraine with their menstrual period or those who have migraines with their menstrual period and at other times of the month as well. The main question the study aims to answer are: • Does fremanazemab, an injectable calcitonin gene-related peptide (CGRP) pathway targeting therapy, decrease migraines associated with menstruation? Participants will * have an evaluation and examination by a headache specialist physician * will receive the study medicine or inactive substitute every three months for two treatments * fill out diaries about their migraines * have tests on saliva to measure hormone levels Researchers will compare the people who get the medicine to those who get the inactive substitute to see if there are differences in response.

NCT Number	NCT06173661
Lead Sponsor	Brigham and Women's Hospital Collaborators: Teva Pharmaceuticals USA
Conditions	Migraine, Menstrual Migraine, Menstrually Related Migraine
Enrollment	72 participants
Start Date	2024-03-01
Primary Completion	2026-07 (estimated)
Study Completion	2026-07 (estimated)
Updated on ClinicalTrials.gov	2026-02-27